Creative Biolabs

Almost all progressive prostate cancers can be repressed by androgen deprivation therapy, but they frequently recur in the form of castrate-resistant prostate cancer (CRPC). Therefore, the treatment of this disease is quite complex. Due to genomic heterogeneity in vivo, it is urgent to develop a reliable in vitro model that faithfully reflects the genetic and phenotype features of prostate cancer. Based on rich experience in drug development, Creative Biolabs has successfully established 3D organoid models such as PDX-derived prostate cancer organoid model to accelerate the progress of your projects.